MARKET

APRE

APRE

Aprea Therapeutics, Inc.
NASDAQ
0.7900
+0.0001
+0.01%
After Hours: 0.7900 0 0.00% 16:10 06/26 EDT
OPEN
0.7548
PREV CLOSE
0.7899
HIGH
0.7900
LOW
0.7218
VOLUME
40.54K
TURNOVER
--
52 WEEK HIGH
2.220
52 WEEK LOW
0.5480
MARKET CAP
9.78M
P/E (TTM)
-0.5125
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APRE last week (0615-0619)?
Weekly Report · 6d ago
Aprea Shareholders Approve Directors, Reverse Split Flexibility
TipRanks · 06/17 21:01
Aprea Therapeutics shareholders elect three Class I directors at annual meeting
PUBT · 06/17 20:16
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Aprea Therapeutics (APRE)
TipRanks · 06/15 12:40
Weekly Report: what happened at APRE last week (0608-0612)?
Weekly Report · 06/15 09:08
Weekly Report: what happened at APRE last week (0601-0605)?
Weekly Report · 06/08 09:07
Pantginis Reiterates Buy on APR-1051 Developer, Keeps $1.20 Price Target After Encouraging ASCO Data and Superior Safety Profile
TipRanks · 06/01 15:55
Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors
Benzinga · 06/01 12:08
More
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Webull offers Aprea Therapeutics Inc stock information, including NASDAQ: APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.